172 related articles for article (PubMed ID: 20213413)
1. Strategies to explore new approaches in the investigation and treatment of osteosarcoma.
Kim SY; Helman LJ
Cancer Treat Res; 2009; 152():517-28. PubMed ID: 20213413
[TBL] [Abstract][Full Text] [Related]
2. A phase I/II dose escalation and activity study of intravenous injections of OCaP1 for subjects with refractory osteosarcoma metastatic to lung.
Benjamin R; Helman L; Meyers P; Reaman G
Hum Gene Ther; 2001 Aug; 12(12):1591-3. PubMed ID: 11529247
[TBL] [Abstract][Full Text] [Related]
3. The Challenge of Developing New Therapies for Childhood Cancers.
Balis FM
Oncologist; 1997; 2(1):I-II. PubMed ID: 10388032
[TBL] [Abstract][Full Text] [Related]
4. Prognostic significance of immunohistochemical expression of ezrin in non-metastatic high-grade osteosarcoma.
Ferrari S; Zanella L; Alberghini M; Palmerini E; Staals E; Bacchini P
Pediatr Blood Cancer; 2008 Apr; 50(4):752-6. PubMed ID: 17886294
[TBL] [Abstract][Full Text] [Related]
5. Management of osteosarcoma pulmonary metastases.
Harting MT; Blakely ML
Semin Pediatr Surg; 2006 Feb; 15(1):25-9. PubMed ID: 16458843
[TBL] [Abstract][Full Text] [Related]
6. Metastasis-associated differences in gene expression in a murine model of osteosarcoma.
Khanna C; Khan J; Nguyen P; Prehn J; Caylor J; Yeung C; Trepel J; Meltzer P; Helman L
Cancer Res; 2001 May; 61(9):3750-9. PubMed ID: 11325848
[TBL] [Abstract][Full Text] [Related]
7. Rapamycin inhibits ezrin-mediated metastatic behavior in a murine model of osteosarcoma.
Wan X; Mendoza A; Khanna C; Helman LJ
Cancer Res; 2005 Mar; 65(6):2406-11. PubMed ID: 15781656
[TBL] [Abstract][Full Text] [Related]
8. "Just Another Statistic".
Machtay M; Glatstein E
Oncologist; 1998; 3(3):III-IV. PubMed ID: 10388105
[TBL] [Abstract][Full Text] [Related]
9. Can cure in patients with osteosarcoma be achieved exclusively with chemotherapy and abrogation of surgery?
Jaffe N; Carrasco H; Raymond K; Ayala A; Eftekhari F
Cancer; 2002 Nov; 95(10):2202-10. PubMed ID: 12412175
[TBL] [Abstract][Full Text] [Related]
10. Metastatic osteosarcoma at diagnosis: prognostic factors and long-term outcome--the French pediatric experience.
Mialou V; Philip T; Kalifa C; Perol D; Gentet JC; Marec-Berard P; Pacquement H; Chastagner P; Defaschelles AS; Hartmann O
Cancer; 2005 Sep; 104(5):1100-9. PubMed ID: 16015627
[TBL] [Abstract][Full Text] [Related]
11. Regarding: Rosenthal DI, Glatstein E. "We've Got a Treatment, but What's the Disease?" The Oncologist 1996;1.
Lunsford LD; Flickinger JC; Larson D
Oncologist; 1997; 2(1):59-61. PubMed ID: 10388030
[TBL] [Abstract][Full Text] [Related]
12. Osteogenic sarcoma of the extremity with detectable lung metastases at presentation. Results of treatment of 23 patients with chemotherapy followed by simultaneous resection of primary and metastatic lesions.
Bacci G; Mercuri M; Briccoli A; Ferrari S; Bertoni F; Donati D; Monti C; Zanoni A; Forni C; Manfrini M
Cancer; 1997 Jan; 79(2):245-54. PubMed ID: 9010097
[TBL] [Abstract][Full Text] [Related]
13. Role of ezrin in osteosarcoma metastasis.
Ren L; Khanna C
Adv Exp Med Biol; 2014; 804():181-201. PubMed ID: 24924175
[TBL] [Abstract][Full Text] [Related]
14. Is there a role for immunotherapy in osteosarcoma?
Loeb DM
Cancer Treat Res; 2009; 152():447-57. PubMed ID: 20213407
[TBL] [Abstract][Full Text] [Related]
15. Osteosarcoma: basic science and clinical implications.
Hayden JB; Hoang BH
Orthop Clin North Am; 2006 Jan; 37(1):1-7. PubMed ID: 16311106
[TBL] [Abstract][Full Text] [Related]
16. Circulating concentrations of IGF-I and IGFBP-3 are not predictive of incidence or clinical behavior of pediatric osteosarcoma.
Rodriguez-Galindo C; Poquette CA; Daw NC; Tan M; Meyer WH; Cleveland JL
Med Pediatr Oncol; 2001 Jun; 36(6):605-11. PubMed ID: 11344491
[TBL] [Abstract][Full Text] [Related]
17. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
Hagemeister FB
Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
[TBL] [Abstract][Full Text] [Related]
18. Osteosarcoma: current status of immunotherapy and future trends (Review).
Mori K; Rédini F; Gouin F; Cherrier B; Heymann D
Oncol Rep; 2006 Mar; 15(3):693-700. PubMed ID: 16465432
[TBL] [Abstract][Full Text] [Related]
19. Synchronous and metachronous skeletal osteosarcomas: the Norwegian Radium Hospital experience.
Brandal P; Bjerkehagen B; Bruland OS; Skjeldal S; Bogsrud TV; Hall KS
Acta Oncol; 2009; 48(8):1165-72. PubMed ID: 19863225
[TBL] [Abstract][Full Text] [Related]
20. The role of Fas/FasL in the metastatic potential of osteosarcoma and targeting this pathway for the treatment of osteosarcoma lung metastases.
Gordon N; Kleinerman ES
Cancer Treat Res; 2009; 152():497-508. PubMed ID: 20213411
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
